CLINICAL TRIALS PROFILE FOR TOPAMAX
✉ Email this page to a colleague
All Clinical Trials for Topamax
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00006205 ↗ | Alcohol Dependency Study: Combining Medication Treatment for Alcoholism | Unknown status | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Phase 2 | 2005-03-01 | The purpose of this study is to learn whether ondansetron and topiramate either alone or in combination is safe and effective in the treatment of alcohol dependence. This 13 week out-patient clinical trial is randomized, double-blind, and placebo-controlled. There are post-study follow up visits 1, 2 and 3 months after the end of the study. Participants will receive ondansetron and topiramate either alone or in combination or a placebo coupled with psychotherapy. |
| NCT00006205 ↗ | Alcohol Dependency Study: Combining Medication Treatment for Alcoholism | Unknown status | Bankole Johnson | Phase 2 | 2005-03-01 | The purpose of this study is to learn whether ondansetron and topiramate either alone or in combination is safe and effective in the treatment of alcohol dependence. This 13 week out-patient clinical trial is randomized, double-blind, and placebo-controlled. There are post-study follow up visits 1, 2 and 3 months after the end of the study. Participants will receive ondansetron and topiramate either alone or in combination or a placebo coupled with psychotherapy. |
| NCT00167245 ↗ | Topiramate for Alcohol and Cocaine Dependence | Completed | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Phase 2 | 2004-09-01 | The primary purpose of this study is to test the effectiveness of topiramate for the treatment of combined alcohol and cocaine dependence. Topiramate is approved for the treatment of seizures. It has not been proven to be effective for the treatment of alcohol or cocaine dependence. |
| NCT00167245 ↗ | Topiramate for Alcohol and Cocaine Dependence | Completed | Kyle Kampman | Phase 2 | 2004-09-01 | The primary purpose of this study is to test the effectiveness of topiramate for the treatment of combined alcohol and cocaine dependence. Topiramate is approved for the treatment of seizures. It has not been proven to be effective for the treatment of alcohol or cocaine dependence. |
| NCT00203190 ↗ | A Double-Blind, Placebo-Controlled Study Examining the Use of Topiramate in the Treatment of Cluster Headache | Terminated | Ortho-McNeil Neurologics, Inc. | Phase 4 | 2004-09-01 | Topiramate is a medication that has been approved by the Food and Drug Administration (FDA) for the treatment of patients with seizures. The trade name for this drug is Topamax®. Topiramate has not been approved by the FDA for the treatment of cluster headache and is experimental for the purposes of this research study. If a subject participates in this study, he/she will increase his/her dose of topiramate rapidly in the first few weeks to try to stop the cluster attacks and then will continue on a maintenance dose of topiramate in order to determine if it can prevent attacks from occurring during that cluster period. We believe that this will lead not only to a faster but a more complete remission of the cluster period. |
| NCT00203190 ↗ | A Double-Blind, Placebo-Controlled Study Examining the Use of Topiramate in the Treatment of Cluster Headache | Terminated | Thomas Jefferson University | Phase 4 | 2004-09-01 | Topiramate is a medication that has been approved by the Food and Drug Administration (FDA) for the treatment of patients with seizures. The trade name for this drug is Topamax®. Topiramate has not been approved by the FDA for the treatment of cluster headache and is experimental for the purposes of this research study. If a subject participates in this study, he/she will increase his/her dose of topiramate rapidly in the first few weeks to try to stop the cluster attacks and then will continue on a maintenance dose of topiramate in order to determine if it can prevent attacks from occurring during that cluster period. We believe that this will lead not only to a faster but a more complete remission of the cluster period. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Topamax
Condition Name
Clinical Trial Locations for Topamax
Trials by Country
Clinical Trial Progress for Topamax
Clinical Trial Phase
Clinical Trial Sponsors for Topamax
Sponsor Name
| Sponsor Name for Topamax | |
| Sponsor | Trials |
| National Institute on Alcohol Abuse and Alcoholism (NIAAA) | 10 |
| National Institute on Drug Abuse (NIDA) | 8 |
| Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 5 |
| [disabled in preview] | 14 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
